Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients

J. M. Rae, M. J. Sikora, N. L. Henry, L. Li, S. Kim, S. Oesterreich, Todd Skaar, A. T. Nguyen, Zeruesenay Desta, Anna Maria Storniolo, D. A. Flockhart, D. F. Hayes, V. Stearns

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

The selective estrogen receptor modulator tamoxifen is routinely used for treatment and prevention of estrogen-receptor-positive breast cancer. Studies of tamoxifen adherence suggest that over half of patients discontinue treatment before the recommended 5 years. We hypothesized that polymorphisms in CYP2D6, the enzyme responsible for tamoxifen activation, predict for tamoxifen discontinuation. Tamoxifen-treated women (n=297) were genotyped for CYP2D6 variants and assigned a 'score' based on predicted allele activities from 0 (no activity) to 2 (high activity). Correlation between CYP2D6 score and discontinuation rates at 4 months was tested. We observed a strong nonlinear correlation between higher CYP2D6 score and increased rates of discontinuation (r2 = 0.935, P = 0.018). These data suggest that presence of active CYP2D6 alleles may predict for higher likelihood of tamoxifen discontinuation. Therefore, patients who may be most likely to benefit from tamoxifen may paradoxically be most likely to discontinue treatment prematurely.

Original languageEnglish
Pages (from-to)258-264
Number of pages7
JournalPharmacogenomics Journal
Volume9
Issue number4
DOIs
StatePublished - 2009

Fingerprint

Cytochrome P-450 CYP2D6
Tamoxifen
Breast Neoplasms
Therapeutics
Alleles
Selective Estrogen Receptor Modulators
Estrogen Receptors
Enzymes

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine
  • Genetics

Cite this

Rae, J. M., Sikora, M. J., Henry, N. L., Li, L., Kim, S., Oesterreich, S., ... Stearns, V. (2009). Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients. Pharmacogenomics Journal, 9(4), 258-264. https://doi.org/10.1038/tpj.2009.14

Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients. / Rae, J. M.; Sikora, M. J.; Henry, N. L.; Li, L.; Kim, S.; Oesterreich, S.; Skaar, Todd; Nguyen, A. T.; Desta, Zeruesenay; Storniolo, Anna Maria; Flockhart, D. A.; Hayes, D. F.; Stearns, V.

In: Pharmacogenomics Journal, Vol. 9, No. 4, 2009, p. 258-264.

Research output: Contribution to journalArticle

Rae, JM, Sikora, MJ, Henry, NL, Li, L, Kim, S, Oesterreich, S, Skaar, T, Nguyen, AT, Desta, Z, Storniolo, AM, Flockhart, DA, Hayes, DF & Stearns, V 2009, 'Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients', Pharmacogenomics Journal, vol. 9, no. 4, pp. 258-264. https://doi.org/10.1038/tpj.2009.14
Rae, J. M. ; Sikora, M. J. ; Henry, N. L. ; Li, L. ; Kim, S. ; Oesterreich, S. ; Skaar, Todd ; Nguyen, A. T. ; Desta, Zeruesenay ; Storniolo, Anna Maria ; Flockhart, D. A. ; Hayes, D. F. ; Stearns, V. / Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients. In: Pharmacogenomics Journal. 2009 ; Vol. 9, No. 4. pp. 258-264.
@article{ad4abac9234444cda36035470d5c2e79,
title = "Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients",
abstract = "The selective estrogen receptor modulator tamoxifen is routinely used for treatment and prevention of estrogen-receptor-positive breast cancer. Studies of tamoxifen adherence suggest that over half of patients discontinue treatment before the recommended 5 years. We hypothesized that polymorphisms in CYP2D6, the enzyme responsible for tamoxifen activation, predict for tamoxifen discontinuation. Tamoxifen-treated women (n=297) were genotyped for CYP2D6 variants and assigned a 'score' based on predicted allele activities from 0 (no activity) to 2 (high activity). Correlation between CYP2D6 score and discontinuation rates at 4 months was tested. We observed a strong nonlinear correlation between higher CYP2D6 score and increased rates of discontinuation (r2 = 0.935, P = 0.018). These data suggest that presence of active CYP2D6 alleles may predict for higher likelihood of tamoxifen discontinuation. Therefore, patients who may be most likely to benefit from tamoxifen may paradoxically be most likely to discontinue treatment prematurely.",
author = "Rae, {J. M.} and Sikora, {M. J.} and Henry, {N. L.} and L. Li and S. Kim and S. Oesterreich and Todd Skaar and Nguyen, {A. T.} and Zeruesenay Desta and Storniolo, {Anna Maria} and Flockhart, {D. A.} and Hayes, {D. F.} and V. Stearns",
year = "2009",
doi = "10.1038/tpj.2009.14",
language = "English",
volume = "9",
pages = "258--264",
journal = "Pharmacogenomics Journal",
issn = "1470-269X",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients

AU - Rae, J. M.

AU - Sikora, M. J.

AU - Henry, N. L.

AU - Li, L.

AU - Kim, S.

AU - Oesterreich, S.

AU - Skaar, Todd

AU - Nguyen, A. T.

AU - Desta, Zeruesenay

AU - Storniolo, Anna Maria

AU - Flockhart, D. A.

AU - Hayes, D. F.

AU - Stearns, V.

PY - 2009

Y1 - 2009

N2 - The selective estrogen receptor modulator tamoxifen is routinely used for treatment and prevention of estrogen-receptor-positive breast cancer. Studies of tamoxifen adherence suggest that over half of patients discontinue treatment before the recommended 5 years. We hypothesized that polymorphisms in CYP2D6, the enzyme responsible for tamoxifen activation, predict for tamoxifen discontinuation. Tamoxifen-treated women (n=297) were genotyped for CYP2D6 variants and assigned a 'score' based on predicted allele activities from 0 (no activity) to 2 (high activity). Correlation between CYP2D6 score and discontinuation rates at 4 months was tested. We observed a strong nonlinear correlation between higher CYP2D6 score and increased rates of discontinuation (r2 = 0.935, P = 0.018). These data suggest that presence of active CYP2D6 alleles may predict for higher likelihood of tamoxifen discontinuation. Therefore, patients who may be most likely to benefit from tamoxifen may paradoxically be most likely to discontinue treatment prematurely.

AB - The selective estrogen receptor modulator tamoxifen is routinely used for treatment and prevention of estrogen-receptor-positive breast cancer. Studies of tamoxifen adherence suggest that over half of patients discontinue treatment before the recommended 5 years. We hypothesized that polymorphisms in CYP2D6, the enzyme responsible for tamoxifen activation, predict for tamoxifen discontinuation. Tamoxifen-treated women (n=297) were genotyped for CYP2D6 variants and assigned a 'score' based on predicted allele activities from 0 (no activity) to 2 (high activity). Correlation between CYP2D6 score and discontinuation rates at 4 months was tested. We observed a strong nonlinear correlation between higher CYP2D6 score and increased rates of discontinuation (r2 = 0.935, P = 0.018). These data suggest that presence of active CYP2D6 alleles may predict for higher likelihood of tamoxifen discontinuation. Therefore, patients who may be most likely to benefit from tamoxifen may paradoxically be most likely to discontinue treatment prematurely.

UR - http://www.scopus.com/inward/record.url?scp=67849116739&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67849116739&partnerID=8YFLogxK

U2 - 10.1038/tpj.2009.14

DO - 10.1038/tpj.2009.14

M3 - Article

C2 - 19421167

AN - SCOPUS:67849116739

VL - 9

SP - 258

EP - 264

JO - Pharmacogenomics Journal

JF - Pharmacogenomics Journal

SN - 1470-269X

IS - 4

ER -